Compare Stocks → Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLCMNASDAQ:BPTHOTCMKTS:CPMDNASDAQ:EYEGNASDAQ:JAGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsBPTHBio-Path$2.49-7.1%$5.01$2.46▼$44.80$1.69M0.351.13 million shs163,632 shsCPMDCannaPharmaRX$0.01$0.01$0.00▼$0.03$6.61M2.12745,141 shsN/AEYEGAB Corporate Bond ETF$34.72-0.3%$1.90$1.44▼$8.18$24.31M0.13935,975 shs5,000 shsJAGXJaguar Health$0.17$0.09$0.05▼$1.22$46.93M1.3551.07 million shs33.93 million shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%0.00%-25.20%-77.68%BPTHBio-Path-7.26%-22.91%-35.58%-73.17%-90.78%CPMDCannaPharmaRX0.00%0.00%-47.09%+733.33%+7.53%EYEGAB Corporate Bond ETF-0.27%-0.01%-2.37%-2.49%+1,680.62%JAGXJaguar Health+1.13%+3.03%+135.32%+47.74%-64.38%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABPTHBio-Path1.3514 of 5 stars3.52.00.00.02.30.00.6CPMDCannaPharmaRXN/AN/AN/AN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCMBellicum PharmaceuticalsN/AN/AN/AN/ABPTHBio-Path3.00Buy$40.001,506.43% UpsideCPMDCannaPharmaRXN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest BLCM, BPTH, CPMD, EYEG, and JAGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACPMDCannaPharmaRXN/AN/AN/AN/A($0.07) per shareN/AEYEGAB Corporate Bond ETF$10K2,430.54N/AN/A$1.26 per share27.56JAGXJaguar Health$9.76M4.81N/AN/A$0.07 per share2.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ABPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)CPMDCannaPharmaRX-$8.53M-$0.03N/A∞N/AN/AN/A-141.66%N/AEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)Latest BLCM, BPTH, CPMD, EYEG, and JAGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ALatest BLCM, BPTH, CPMD, EYEG, and JAGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/28/2024EYEGAB Corporate Bond ETFMonthly$0.15724/1/20244/2/20244/5/20242/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCMBellicum PharmaceuticalsN/A3.043.04BPTHBio-PathN/A1.601.60CPMDCannaPharmaRXN/AN/AN/AEYEGAB Corporate Bond ETF0.013.073.07JAGXJaguar Health6.332.001.34OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCMBellicum Pharmaceuticals4.93%BPTHBio-Path5.74%CPMDCannaPharmaRXN/AEYEGAB Corporate Bond ETF64.16%JAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipBLCMBellicum Pharmaceuticals10.30%BPTHBio-Path3.05%CPMDCannaPharmaRX1.27%EYEGAB Corporate Bond ETF58.20%JAGXJaguar Health0.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableBPTHBio-Path10680,000658,000OptionableCPMDCannaPharmaRX6660.63 million652.24 millionNot OptionableEYEGAB Corporate Bond ETF14700,0005.28 millionNot OptionableJAGXJaguar Health49276.22 million276.16 millionNo DataBLCM, BPTH, CPMD, EYEG, and JAGX HeadlinesSourceHeadline3 Obstacles Investors Face When Buying Penny Stockspennystocks.com - April 23 at 6:37 AMNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Careaccesswire.com - April 22 at 8:45 AMJaguar Health (NASDAQ:JAGX) Now Covered by StockNews.comamericanbankingnews.com - April 22 at 2:16 AMJaguar Health gets grant for treating secretory diarrhea associated with microvillous inclusion diseasepharmaceutical-technology.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry…pharmiweb.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Careaccesswire.com - April 18 at 8:30 AMJaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US marketpharmabiz.com - April 18 at 6:22 AMWhy Jaguar Health Stock Is Up Todaymsn.com - April 17 at 2:20 AMGold Moves Higher; Morgan Stanley Earnings Top Viewsmarkets.businessinsider.com - April 17 at 2:20 AMWhy Is Jaguar Health (JAGX) Stock Up 44% Today?investorplace.com - April 16 at 11:34 AMJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Careaccesswire.com - April 16 at 8:30 AMS&P 500 Down 1%; Delta Air Lines Posts Upbeat Earningsbenzinga.com - April 10 at 3:37 PMJaguar Health shareholders approve reverse stock splitmsn.com - April 10 at 3:37 PMWhat Is Going on With Jaguar Health (JAGX) Stock Today?investorplace.com - April 10 at 10:40 AMJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersfinanznachrichten.de - April 10 at 1:23 AMWhy Jaguar Health Stock Is Soaring After-Hoursmsn.com - April 9 at 8:04 PMJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersaccesswire.com - April 9 at 4:15 PMJaguar Health Granted Extension Until August 13, 2…pharmiweb.com - April 8 at 9:51 AMJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirementaccesswire.com - April 8 at 8:30 AMJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)finance.yahoo.com - April 3 at 9:48 AMJaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:47 PMJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar Internationalaccesswire.com - April 2 at 8:50 AMJAGX Stock Earnings: Jaguar Health Misses Revenue for Q4 2023investorplace.com - April 1 at 2:08 PMJaguar Health, Inc.: Jaguar Health Reports 2023 Financial Resultsfinanznachrichten.de - April 1 at 10:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Bio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.CannaPharmaRXOTCMKTS:CPMDCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.